Chronic and Acute Heart Failure

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-12-15

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

There is a clear need for new treatments for heart failure, as mortality and morbidity rates, although improving, remain high. Heart failure already represents the leading cause of hospitalization for patients over the age of 65 in Western markets and the aging population in these markets will surely lead to growth in the prevalence of the disease and an increase in healthcare expenditure.


Scope

  • Assessment of the patient potential, including patient segmentation for developmental chronic and acute heart failure products
  • Overview of the chronic and acute heart failure R&D pipeline with detailed information on the classes in development
  • Commercial analysis, supported by the views of key opinion leaders, of key compounds in development in terms of their ability to satisfy unmet needs
  • Sales forecasts for key late-stage developmental chronic and acute heart failure products in the seven major markets to 2014


    • Report Highlights
    The late-stage heart failure pipeline is weak in terms of quantity and quality, 81% of products are in Phase I and II of development. The majority of pipeline products are being developed for chronic heart failure with only 33% being developed for acute heart failure.

    Developmental chronic heart failure products hold little commercial promise because they are primarily being developed as add-on therapies with niche-focused launch strategies and the increased use of devices in this area form strong competition.

    The acute heart failure pipeline has high commercial potential but safety issues have led to disappointment for levosimendan, leaving tolvaptan as the most promising acute heart failure product in the pipeline.


    Reasons to Purchase

  • Gain insight into the current and future prospects for the chronic and acute heart failure market from key opinion leaders
  • Identify the opportunities and risks for late stage developmental products based on a structured assessment of clinical and commercial attractiveness
  • View independent sales forecasts for drugs in late-stage development for treatment of chronic and acute heart failure

    • Table of Contents

    Other users found this report page using the following search terms: heart failure heart failure acute chronic stage late vs 3 definition trial

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.